A Phase 3 interventional study of Torsemide and Furosemide in Heart Failure, sponsored by Duke University. Completed at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Duke University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing furosemide in Heart Failure — 5 open to participants now, 5 under way, 1 of them phase 3. Furosemide · Heart Failure.
Among the 36 studies testing furosemide in Heart Failure, this one has the largest enrollment of the 35 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 3, and was the 22nd registered.
6,332 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →5 of the 36 studies testing furosemide in Heart Failure are open now, in 2 countries. Recruiting first, the newest first:
Lakeland Regional Health Systems, Inc. · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18–80
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark
Ages 18+
Heart Center Research, LLC · Sites in United States
Ages 19+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–100
By country, each count listing its studies:
Furosemide: first FDA approval 1966 (LASIX), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 7 · Phase 4 17
First in 2000; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,973 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 42 across the 35 interventional studies. Of the 23 that completed or were terminated, 9 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 36 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 273 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.
64 studies in Heart Failure by Duke University: 6 open now, 7 under way, none of them phase 3. Of 53 finished, 25 (47%) have results posted.
Among the 64 studies in Heart Failure by Duke University, this one is the 5th largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2018, is one of 8 in phase 3, and was the 43rd registered.
Duke University’s Heart Failure studies by the year they started, since 2002.
3 of the studies testing furosemide in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06979726University of FloridaGator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure | 2026-11-30 |
| NCT05276219Copenhagen University Hospital, RigshospitaletDECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure | 2027-05-01 |
| NCT07263035Lakeland Regional Health Systems, Inc.Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing furosemide in Heart Failure, from their registry updates:
Among Duke University’s 64 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over 12 months in patients with heart failure who are hospitalized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient hospitalized (≥ 24 hours or over a change in calendar date) with worsening of chronic heart failure, or new diagnosis of heart failure AND meets one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
Drug: Torsemide
Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg. For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows: 1 mg oral torsemide = 2-4 mg oral furosemide 1 mg oral or intravenous bumetanide = 40 mg oral furosemide
Drug: Furosemide
Loop diuretic
Loop diuretic
All-cause Mortality, as Measured by Follow-up Phone Call or NDI
Death information was obtained from the Call Center through 30 months for patients 1-500, through 24 months for patients 501-1000, through 18 months for patients 1001-1500, and through 12 months for the remaining patients (except those who were randomized \< 12 months when the study was stopped by the DSMB). Also death information was obtained through searches of the 2018-2021 National Death Index (NDI) database.
Time frame: up to 30 months
All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)
The time-to-event analysis of all-cause mortality or all-cause primary re-hospitalization was based on the time from randomization through death or the first primary re-hospitalization through 12 months. Patients who died or whose first all-cause re-hospitalization was after month 12 were censored at month 12. Patients who did not have a re-hospitalization and were alive were censored at the minimum of the time of the last re-hospitalization assessment or month 12.
Time frame: up to 12 months
Total Re-hospitalizations, as Measured by Follow-up Phone Call
Total all-cause primary re-hospitalization was defined as a hospitalization after the index hospitalization through month 12 that met one of the following criteria: 1.) at least a 24-hour stay (or a change in calendar date if the time of admission/discharge is not available) or 2.) reported as an in-patient admission by the patient/proxy with an admission date (complete or month and year) and no discharge date (i.e., length of stay could not be derived). Unit of measurement is the total number of re-hospitalizations for each subject (e.g., if a subject had 3 re-hospitalizations, then the outcome is 3 for the subject).
Time frame: up to 12 months
All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)
All-cause mortality or all-cause hospitalization over 30 days
Time frame: 30 days
Change in Health-related Quality of Life (QOL), as Measured by Follow-up Phone Call
QOL as assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) (range, 0-100 with 100 indicating best health status). The KCCQ was administered prior to randomization (collected by the site) and at Months 1, 6 and 12 (ascertained at the Call Center visits). The outcome is the least square means in Torsemide and Furosemide groups where the difference = Torsemide mean minus Furosemide mean at the monthly assessment.
Time frame: Baseline, 1 month, 6 months, 12 months
Symptoms of Depression as Measured by the Patient Health Questionnaire-2 (PHQ-2)
Depression was assessed by the Patient Health Questionnaire-2 (PHQ-2) over 12 months. The PHQ-2 inquires about the frequency of depressed mood and anhedonia (inability to feel pleasure) over the past two weeks. The responses to the questions are scored 0 = Not at all, 1 = Several days, 2 = More than half the days, and 3 = Nearly every day. The PHQ-2 total score is obtained by adding the score for each question. The PHQ-2 total score ranges from 0-6. Reported as the number of patients with a total score \<3 versus \>=3.
Time frame: Month 1, month 6, month 12
| Milestone | Torsemide | Furosemide |
|---|---|---|
| Started | 1431 | 1428 |
| Completed | 1378 | 1368 |
| Not completed | 53 | 60 |
Death information was obtained from the Call Center through 30 months for patients 1-500, through 24 months for patients 501-1000, through 18 months for patients 1001-1500, and through 12 months for the remaining patients (except those who were randomized \< 12 months when the study was stopped by the DSMB). Also death information was obtained through searches of the 2018-2021 National Death Index (NDI) database.
| Participants | Torsemide | Furosemide |
|---|---|---|
| All-cause Mortality, as Measured by Follow-up Phone Call or NDI | 373 | 374 |
The time-to-event analysis of all-cause mortality or all-cause primary re-hospitalization was based on the time from randomization through death or the first primary re-hospitalization through 12 months. Patients who died or whose first all-cause re-hospitalization was after month 12 were censored at month 12. Patients who did not have a re-hospitalization and were alive were censored at the minimum of the time of the last re-hospitalization assessment or month 12.
| Participants | Torsemide | Furosemide |
|---|---|---|
| All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death) | 677 | 704 |
Total all-cause primary re-hospitalization was defined as a hospitalization after the index hospitalization through month 12 that met one of the following criteria: 1.) at least a 24-hour stay (or a change in calendar date if the time of admission/discharge is not available) or 2.) reported as an in-patient admission by the patient/proxy with an admission date (complete or month and year) and no discharge date (i.e., length of stay could not be derived). Unit of measurement is the total number of re-hospitalizations for each subject (e.g., if a subject had 3 re-hospitalizations, then the outcome is 3 for the subject).
| re-hospitalizations | Torsemide | Furosemide |
|---|---|---|
| Total Re-hospitalizations, as Measured by Follow-up Phone Call | 940 | 987 |
All-cause mortality or all-cause hospitalization over 30 days
| Participants | Torsemide | Furosemide |
|---|---|---|
| All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death) | 149 | 157 |
QOL as assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) (range, 0-100 with 100 indicating best health status). The KCCQ was administered prior to randomization (collected by the site) and at Months 1, 6 and 12 (ascertained at the Call Center visits). The outcome is the least square means in Torsemide and Furosemide groups where the difference = Torsemide mean minus Furosemide mean at the monthly assessment.
| score on a scale | Torsemide | Furosemide |
|---|---|---|
| Baseline to Month 1 | 69.52 (67.53 to 71.51) | 68.22 (66.22 to 70.23) |
| Baseline to Month 6 | 70.61 (68.53 to 72.70) | 71.01 (68.91 to 73.10) |
| Baseline to Month 12 | 70.00 (67.85 to 72.15) | 69.98 (67.80 to 72.16) |
Depression was assessed by the Patient Health Questionnaire-2 (PHQ-2) over 12 months. The PHQ-2 inquires about the frequency of depressed mood and anhedonia (inability to feel pleasure) over the past two weeks. The responses to the questions are scored 0 = Not at all, 1 = Several days, 2 = More than half the days, and 3 = Nearly every day. The PHQ-2 total score is obtained by adding the score for each question. The PHQ-2 total score ranges from 0-6. Reported as the number of patients with a total score \<3 versus \>=3.
| Participants | Torsemide | Furosemide |
|---|---|---|
| Month 1 — PHQ-2 score < 3 | 790 | 813 |
| Month 1 — PHQ-2 score > = 3 | 148 | 150 |
| Month 6 — PHQ-2 score < 3 | 658 | 672 |
| Month 6 — PHQ-2 score > = 3 | 113 | 119 |
| Month 12 — PHQ-2 score < 3 | 533 | 537 |
| Month 12 — PHQ-2 score > = 3 | 95 | 82 |
Collected over All-Cause Mortality data was collected for up to 30 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Torsemide | 373/1,431 (26.1%) | — | — |
| Furosemide | 374/1,428 (26.2%) | — | — |
| Age, Continuous(years) | Torsemide | Furosemide | Total |
|---|---|---|---|
| Mean | 64 ± 14 | 65 ± 14 | 64.5 ± 14 |
| Sex: Female, Male(Participants) | Torsemide | Furosemide | Total |
|---|---|---|---|
| Female | 498 | 557 | 1055 |
| Male | 933 | 871 | 1804 |
| Ethnicity (NIH/OMB)(Participants) | Torsemide | Furosemide | Total |
|---|---|---|---|
| Hispanic or Latino | 75 | 80 | 155 |
| Not Hispanic or Latino | 1355 | 1345 | 2700 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Race (NIH/OMB)(Participants) | Torsemide | Furosemide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 9 | 3 | 12 |
| Asian | 37 | 26 | 63 |
| Native Hawaiian or Other Pacific Islander | 13 | 7 | 20 |
| Black or African American | 474 | 494 | 968 |
| White | 831 | 837 | 1668 |
| More than one race | 65 | 58 | 123 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Region of Enrollment(Participants) | Torsemide | Furosemide | Total |
|---|---|---|---|
| United States | 1431 | 1428 | 2859 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Jul 2022, 48 months.
Results were first posted in Oct 2025, 3 years 2 months after primary completion.
Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 48 months is close to that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Torsemide · Furosemide